Vericel reported record first-quarter revenue and raised its full-year 2026 outlook, supported by strong growth in its MACI cartilage repair franchise and Burn Care business. The company also expects NexoBrid procurement revenue under a new federal contract, adding another growth driver. The update signals improving operating momentum and a more constructive full-year outlook for VCEL.
Vericel reported record first-quarter revenue and raised its full-year 2026 outlook, supported by strong growth in its MACI cartilage repair franchise and Burn Care business. The company also expects NexoBrid procurement revenue under a new federal contract, adding another growth driver. The update signals improving operating momentum and a more constructive full-year outlook for VCEL.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.68
Ticker Sentiment
